Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry Study

Kent & Canterbury Hospital, Canterbury

Chesterfield Royal Hospital, Chesterfield

Royal Cornwall Hospital; Dept of Clinical Oncology, Cornwall

Castle Hill Hospital; The Queens Centre for Oncology and Haematology, Cottingham

Hairmyres Hospital; Oncology Dept, East Kilbride

Queen Elizabeth Hospital, Gateshead

Raigmore Hospital, Inverness

Forth Valley Royal Hospital ; Oncology Department, Larbert

Queen Elizabeth Hospital, London

Royal Marsden Hospital; Dept of Med-Onc, London

Charing Cross Hospital; Medical Oncology., London

Macclesfield District General Hospital, Macclesfield

Maidstone Hospital; Kent Oncology Centre, Maidstone

Christie Hospital Nhs Trust; Medical Oncology, Manchester

James Cook University Hospital; Oncology and Radiology, Middlesbrough

Northampton General Hospital NHS Trust;Oncology Unit, Northampton

Mount Vernon & Watford Trust Hospital; Dept. of Clinical Oncology, Northwood

Norfolk & Norwich University Hospital; Oncology Department, Norwich

Nottingham City Hospital; Oncology, Nottingham

Derriford Hospital; Plymouth Oncology Centre, Plymouth

Royal Preston Hosp; Rosemere Cancer Ctr, Preston

North Wales Cancer Treatment Centre, Glan Clwyd Hospital, Rhyl

Scarborough General Hospital, Scarborough

Royal Shrewsbury Hospitals Nhs Trust; Oncology, Shrewsbury

Royal Marsden Hospital; Dept of Medical Oncology, Sutton

Singleton Hospital; Pharmacy, Swansea

Great Western Hospital, Swindon Cancer Research Unit; Osprey Unit Level 3, Swindon

Pinderfields Hospital; Clinical Research Team, Rowan House, Wakefield

Yeovil District Hospital; Macmillan Unit, Yeovil

Airedale General Hospital; Oncology, York